High Throughput Screening Market Research Report Information By Product & Service (Reagents &, Assay Kits Instruments, Consumables &, Accessories, Software and Services), By Technology (Cell-Based Assays, 2D Cell Culture, 3D Cell Culture [Scaffold-Based Technologies (Hydrogels Inert Matrix Micropatterned Surfaces)], Scaffold-free Technologies (Microplate), Hanging-drop Plates, Ultra-low Binding Plates, Other Scaffold-free Technologies), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Til

Global High Throughput Screening Market Overview

High Throughput Screening Market size was valued at USD 19.1 billion in 2022. The High Throughput Screening Market industry is projected to grow from USD 21.2 billion in 2023 to USD 47.8 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.70% during the forecast period (2023 - 2032).

The factors contributing to the growth of the market are the growing genomic research activities, rising demand for personalized medicine, increasing investment in research and development, and increasing awareness and adoption.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

High Throughput Screening Market Trends

•  Growing Genomic Research Activities

The growing genomic research activities is a significant driver in the global for high throughput screening market. In recent years, the field of genomic research has witnessed a tremendous surge in activities, driven by advancements in technology and increasing interest in understanding the human genome and its impact on health and disease. One of the key technologies revolutionizing this field is high-throughput screening, also known as next-generation screening (NGS). High-throughput screening enables researchers to sequence large volumes of DNA or RNA rapidly and cost-effectively, providing valuable insights into the genetic makeup of organisms.

The high-throughput screening market is experiencing substantial growth due to the rising demand for personalized medicine. Personalized medicine, also known as precision medicine, is an innovative approach that considers an individual's unique genetic makeup, lifestyle, and environmental factors to tailor medical treatments and interventions. High-throughput screening, with its ability to sequence large volumes of DNA or RNA rapidly and cost-effectively, plays a pivotal role in the advancement of personalized medicine. 

One of the primary drivers behind the increasing demand for personalized medicine is the growing recognition that individuals respond differently to treatments due to their unique genetic variations. High-throughput screening enables the identification of disease-associated genetic variants and offers insights into the genetic factors underlying the efficacy and safety of specific therapies. By analyzing an individual's genetic information, healthcare professionals can determine the most suitable treatment options and optimize dosages, resulting in improved patient outcomes.

Therefore, growing genomic research activities, rising demand for personalized medicine, and technological advancements industry are fueling market growth.

High Throughput Screening Market Segment Insights

High Throughput Screening Product & Services Insights

Based on product & service, the High Throughput Screening Market has been segmented into consumables, instruments, and software & services. The consumables segment dominated the market in 2022, while the software & services segment is projected to be the fastest-growing during the forecast period, 2023–2032.

High Throughput Screening Technology Insights

Based on technology, the High Throughput Screening Market has segmented into cell-based assays, Lab-on-a-Chip (LOC), ultra-high-throughput screening, label-free technology, and others. The The cell-based assays segment dominated the market in 2022 and the Lab-on-a-Chip (LOC) segment is projected to be the fastest growing segment during the forecast period, 2023–2032.

High Throughput Screening Application Insights

Based on application, the High Throughput Screening Market has segmented into drug discovery, biochemical screening, cell & organ-based screening, and others. The drug discovery segment dominated the market in 2022 and the cell & organ-based screening segment is projected to be the fastest growing segment during the forecast period, 2023–2032.

High Throughput Screening End User Insights

Based on end user, the High Throughput Screening Market has segmented into pharmaceutical and biotechnology companies, research institutes and organizations, and contract research organizations. The pharmaceutical and biotechnology companies segment dominated the market in 2022 and the contract research organizations segment is projected to be the fastest growing segment during the forecast period, 2023–2032.

FIGURE 2: HIGH THROUGHPUT SCREENING MARKET, BY END USER, 2022 & 2032 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

High Throughput Screening Regional Insights

By region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. . North America accounted for the largest market share of 42.96% in 2022 and Asia-Pacific is projected to grow at the highest CAGR of 11.01% during the forecast period. Furthermore, market growth is driven by increasing clinical trial numbers across the globe, and growing research & development. Moreover, the below graph represents the number of clinical trials for each region started in 2022.  

The market growth has been driven by inorganic strategies to expand high-throughput screening (HTS) solutions to measure biochemical activities and identify binding interactions, which accelerate the timeline and reduce costs to identify lead drug candidates. 

For instance, in January 2023, Charles River Laboratories International, Inc. (US) acquired SAMDI Tech, Inc. (US), a leading provider of HTS solutions to expand HTS portfolio

Further, the major countries studied are: The US, Canada, Brazil, Germany, France, the UK, Italy, Spain, China, India, Japan, South Korea, Australia.

FIGURE 3: HIGH THROUGHPUT SCREENING MARKET, BY REGION, 2022 & 2032 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

The growth of the European high-throughput screening market is driven by promoting HTS projects to accelerate the discovery of a lead molecule for a new drug. For instance, in March 2023, SCREENTECH opened under the complementary plan for biotechnology in Catalonia (Spain). This initiative prioritized the development of new projects based on the drug screening and drug-target interaction analysis platform at IRB Barcelona (US).

Moreover, the high indulgence of high-throughput screening start-up developers such as CN Bio (UK), Evosep (Denmark), Ovizio (Belgium), and Oxford Nanopore Technologies plc. (UK) through raising funding and incorporating innovation is creating huge opportunities for the region’s growth. For instance, in February 2023, CN Bio (UK) launched the PhysioMimix single-organ higher throughput (HT) system. 

The system was designed for earlier stages of the human liver model and through this large-scale drug discovery is possible. Furthermore, the Germany High Throughput Screening Market held the largest market share in 2022 and Rest of Europe High Throughput Screening Market is the fastest growing market in the Europe region.

The Asia-Pacific high-throughput screening market has shown immense growth in the last decade owing to increasing clinical trials. As per Pharma Intelligence UK Limited (UK), the Asia-Pacific (APAC) region accounted for 50% of clinical trial activity globally in 2021. Moreover, in APAC, China accounted for 45%, followed by Japan (21%), South Korea (13%), Australia (11%), and India (10%) in 2021.

High Throughput Screening Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product, which will help the High Throughput Screening Market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the High Throughput Screening industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Agilent Technologies Inc. (Agilent) provides tools, supplies, consumables, services, and software for the full workflow of a laboratory. Its three operating segments are Agilent CrossLab, Diagnostics and Genomics, and Life Sciences and Applied Markets. The company offers, among other things, clinical and diagnostic tests, automation systems, microarray solutions, components for liquid and gas chromatography, and microarray solutions. Agilent's measurement technologies cater to a wide range of customers through its three operational segments: diagnostics and genomics, cross lab (consisting of consumables and services related to life science and applied tools), and life science and applied tools. Agilent distributes its products to customers directly through distributors, manufacturers' agents, resellers, and online merchants. Furthermore, it has operations in the Americas, Europe, and Asia. 

Moreover, Agilent Technologies, Inc (US) acquired Resolution Bioscience Inc (US) to Strengthen its Leadership Position in the Growing Cell Analysis Segment. The acquisition enhances and broadens Agilent's capabilities in NGS-based cancer diagnostics and provides the business with access to cutting-edge technology to better serve the demands of the rapidly growing precision medicine segment.

Key Companies in the High Throughput Screening Market includes.

• Corning Incorporated


• Merck KGaA


• Tecan Trading AG


• Agilent Technologies Inc


• PerkinElmer Inc


• Luminex Corporation


• Hoffmann-La Roche Ltd


• Promega Corporation


• Beckman Coulter Inc


• Hamilton Company


• Others

High Throughput Screening Industry Developments

March 2022: Promega Corporation (US) launched Lumit assays for researchers studying immunity and inflammation. The immunoassays were designed to aid in basic research or high-throughput screening for drug discovery and development.

December 2020: Beckman Coulter (US) launched a high-throughput COVID-19 antigen test assay. This test can analyze200 samples per hour which provide high throughput screening within 30 minutes as well as referring the scalability constraints of POC tests.

High Throughput Screening Market Segmentation

High Throughput Screening Product & Services Outlook

• Consumables
  
  
  
  • Reagents and Assay Kits
  
  
  • Laboratory Equipments
  
  
  
  


• Instruments
  
  
  
  • Liquid Handling Systems
  
  
  • Detections Systems
  
  
  • Others
  
  
  
  


• Software & Services

High Throughput Screening Technology Outlook

• Cell-Based Assays
  
  
  
  • 2D Cell Culture
  
  
  • 3D Cell Culture
    
    
    
    • Scaffold-Based Technologies
    
    
    • Scaffold-Free Technologies
    
    
    
    
  
  
  • Perfusion Cell Culture
  
  
  • Reporter Based Assay
  
  
  
  


• Lab-on-a-Chip (LOC)


• Ultra-High-Throughput Screening


• Label-Free Technology


• Others

High Throughput Screening Application Outlook

• Drug Discovery


• Biochemical Screening


• Cell- & Organ-Based Screening


• Others

High Throughput Screening End User Outlook

• Pharmaceutical and Biotechnology Companies


• Academic and Government Research Institutes


• Contract Research Organizations

High Throughput Screening Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • India
  
  
  • Japan
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America